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Summary 
Major histocompatibility (MHC)  class  I  glycoproteins are specialized to present to CD8 + T 
cells, peptides that originate from proteins synthesized within the cytoplasm. Conventional killed 
vaccines are unable to get into the cell cytoplasm and therefore fail to expand the CD8 + T cell 
population. We have created a novel influenza transfectant virus, R10, which carries an immuno- 
genic peptide from the nucleoprotein (NP) of PK8 influenza virus in its hemagglutinin (HA) 
and another similar peptide in its HK influenza virus NP. The two peptides are both presented 
by H-2D b and bind with approximately equal affinity. They can compete with one another for 
binding to H-2D b. Yet in cells infected with K10, both peptides are presented efficiently enough 
to expand the respective cytotoxic T lymphocyte (CTL) precursors in vivo and to serve as targets 
for CTL lysis in vitro. It has been proposed that proteins bearing signal sequences may be processed 
by a transporter-independent pathway. To investigate this, we infected the transporter-deficient 
cell line RMA-S with the R10 virus to see if the NP peptide expressed by the HA would be 
presented. The result shows that even the presence of a signal peptide in the HA does not over- 
come the lack of a transporter function, suggesting that the presentation of both peptides is 
dependent on functional transporter proteins. Our data also suggest the feasibility of creating 
by genetic engineering, recombinant vaccines expressing multiple epitopes that can effectively 
stimulate a cellular immune response. 
C 
TL recognize short peptides derived from the processing 
of intracellular proteins that  are presented at the cell 
surface by class I molecules of the major histocompatibility 
loct/s (1, 2). The isolation of naturally processed peptides from 
class  I antigens has shown that for each allele  the peptides 
exhibit a "motif" characterized by a few amino acids,  and 
that these residues are crucial for binding to MHC antigens 
(3-7).  This concept was strengthened by the resolution of 
the crystal structure of class I molecules showing that the 
consensus residues dock within pockets of the antigen-binding 
cleft (8-10). 
Sensitization of cells with synthetic peptides showed that 
MHC molecules can bind and present specific peptides as well 
as  analogues  that  differ in  structure  and length  (10,  11). 
Whereas numerous studies have focused on the recognition 
of natural peptides and synthetic analogues by CD4 T cells 
(12-14),  there is limited information on the effects of ana- 
logues on the presentation of endogenous viral peptides as- 
sociated with class I antigens to CD8 + T  cells  (15).  These 
questions are particularly important for the development and 
the use of recombinant vaccines containing multiple epitopes. 
Our study was aimed at investigating the presentation of 
two  influenza virus  nucleoprotein  (NP)l-derived  peptides 
that bind to the same allele (i.e.,  Db).  Conceptually, these 
two NP peptides may be considered to be analogues. To carry 
out this study, we took advantage of a new reverse genetics 
approach allowing the expression of foreign epitopes or an- 
tigens by influenza virus. This method is based on the rescue 
of cDNA-derived RNA into infectious viral particles (16). 
Using this technique it was possible to express in a hemag- 
glutinin (HA) molecule the epitopes of HA of different virus 
Abbreviations used in this paper'. ER, endoplasmic reticulum; HA, hemag- 
glutinin;  NP, nucleoprotein;  SP, spleen cell; TAP, transporter-associated 
with antigen  processing. 
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HIV-1 glycoprotein (gp120) protein (18), and the epitope of 
the circumsporozoite protein of Plasmodium yoelii (19).  For 
the present study, we created a chimeric influenza virus by 
inserting  into  antigenic  site  E  of  the  HA  of  influenza 
A/WSN/33  virus, a nonamer peptide derived from the NP 
of influenza A/PR/8/34  virus (PRS). The chimeric HA gene 
was then transferred into a virus that derives the remaining 
seven RNA segments from influenza A/HK/8/68 virus (HK). 
Therefore, our chimeric virus (K10) expresses the PRS-NP 
peptide within the HA and the HK-NP peptide from its NP 
protein.  PRS-NP  and HK-NP peptides  share the  same an- 
choring motifs and differ by only two amino  acid residues 
(20). This influenza virus transfectant expressing both pep- 
tides was used to study: (a) whether antigenic competition 
hinders  the ef~cient presentation  of two peptide  analogues 
presented  to  CTLs  by  the  same  allele;  and  (b)  how  the 
transporter-associated with antigen processing (TAP) depen- 
dent transport system (21) affects the ef~ciency with which 
peptides are presented from proteins with and without signal 
sequences. 
Materials and Methods 
Mice.  C57BL/6 mice were purchased from The Jackson Labo- 
ratory (Bar Harbor, ME). 
Viruses.  Influenza A/PR/8/34 and A/HK/8/68 viruses were 
grown in embryonated eggs, whereas the chimeric influenza virus 
R10 was grown in Madin Darby canine kidney (MDCK) as previ- 
ously described (16). 
Cell Lines.  Eb4, RMA, and RMA-S cells (kindly donated by 
Dr. J. Yewdell, National Institutes of Health, Bethesda, MD) were 
grown in DMEM medium supplemented with 10% FCS and were 
used as targets for the cytotoxic assays. 
Peptides.  Peptide ASNENMETM corresponding to amino acid 
residues  366-374  of the  influenza  virus  A/PR/8/34  NP  and 
ASNENMDAM corresponding to amino acid residues 366-374 of 
the influenza A/HK/8/68  NP were synthesized in the Depart- 
ment of Pharmacology,  Mount  Sinai  Medical Center and were 
purified by HPLC.  Two  peptides corresponding  to  amino  acid 
residues 229-237  (CKGVNKEYL) and 489-497  (QGINNLDNL) 
of the SV40 T  antigen  were a gift from Dr. J.  Yewdell. 
Construction of the Transfectant Virus TE Expressing the PRS-NP 
Epitope.  Plasmid pTE was constructed by replacing the BstEII- 
HindllI  fragment  of pT3/WSN-HA  containing  the  influenza 
A/WSN/33 virus HA gene (19) with a PCR product, in which 
the nucleotide sequence encoding seven amino acid residues at the 
antigenic site E of the HA was replaced by the sequence encoding 
the PRS-NP peptide ASNENMETM.  Rescue of infectious virus 
carrying the pTE plasmid-derived RNA was done as described (17). 
The  nucleotide  sequence  encoding  the  PK8-NP  peptide  was 
confirmed by direct sequencing of the viral HA segment as previ- 
ously described  (17). All other genes of the virus are derived from 
influenza A/WSN/33  virus. 
Generation of the Reassortant RIO Virus.  The reassortment of 
viruses has been done as described (22).  Briefly, Madin Darby ca- 
nine kidney (MDCK) cells were infected with influenza HK virus 
and UV-irradiated TE virus. The supernatant of the infected cells 
was used for plaque assay in the presence of anti-HK antiserum. 
From  10 individually isolated plaques,  R10 was genotyped and 
shown to contain its HA gene derived  from the TE virus and its 
remaining genes from HK virus (Fig.  1). 
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Figure  1.  Construction of the transfectant TE virus and the reassortant 
virus R10. (A) The amino acid sequences of the Db-restricted NP-specific 
CTL epitopes of influenza PR8 and HK viruses. Differences  between the 
peptides are underlined. (B) The transfectant virus TE was designed to 
express the PR8 virus-specific CTL epitope in site E of the influenza 
A/WSN/33 virus HA. It was constructed by replacing the 7-amino acid 
peptide oftbe HA with the 9-amino acid CTL pepride (indicated in italics). 
(C) The reassortant virus K10 was generated by mixed infection of the 
transfectant TE virus and the influenza A/HK/8/68 virus. It derives the 
HA gene (RNA segment 4) from the TE virus and the remaining genes 
from HK virus. The CTL epitopes of the NP proteins of PR8 and HK 
viruses are indicated in black or gray boxes, respectively.  It should be noted 
that the NP-specific PR8 CTL epitope is also present in the NP of the 
TE virus but not in reassortant virus R10 which contains HI( virus NP 
segment. 
Induction of CTL Response.  C57BL/6  mice were immunized 
intraperitoneally with 0.2 ml of a viral suspension containing 107 
PFU of PRS, HK, or R10 viruses.  7 d later, spleen cells (SC) were 
obtained and restimulated in vitro for 5 d with irradiated SC alone 
or coated with PR8-NP or HK-NP peptides or SC infected with 
PRS, HK, or KlO viruses as previously described (23). CTL clones 
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lated with SC coated with NP peptides. 
Cytolysis Assay.  EL-4,  RMA, or RMA-S cells coated with PR- 
NP or HK-NP peptides or infected with PR8, HK, or R10 viruses 
were labeled with Na sl CrO4 (100 #Ci/106 cells) for 1 h at 37~ 
After two washings, the cells were transferred to V-bottom 96-well 
plates, the effector cells were added, and the mixture was incubated 
at 37~  in 7% CO2.4 h later, the supernatant was harvested and 
counted. The maximum chromium release was determined by in- 
cubating the cells with 1% NP-40. The percentage of specific lysis 
is calculated according to the following  formula:  100  x  [(cpm 
samples  -  cpm spontaneous release)/(cpm maximum  release - 
cpm spontaneous release)]. 
Immunostaining.  RMA-S cells were infected with 107 PFU of 
PR8 or R10 viruses. The presence of HA on the surface was de- 
tected by immunostaining  as previously described (24). For immu- 
nostaining of cells, mAbs PY211 and 2G9 specific for the HA of 
PR8 virus and the HA of WSN virus, respectively, were used. As 
a negative control, mAb PY206 specific for the HA of X31 virus 
was used. Identical samples of  infected cells were analyzed for hemad- 
sorption. 
Results 
Recognition of PR8 and HK-NP Peptides.  The two pep- 
tides which are derived from the NPs of influenza PR8 and 
HK viruses and bind to the D b MHC glycoprotein,  differ 
by two amino acids. The PRS-NP peptide has glutamic acid 
and threonine at positions 7 and 8 respectively, whereas the 
HK-NP peptide has aspartic acid and alanine in these posi- 
tions (3). CTLs are able to discriminate between these subtle 
differences,  as  shown by our  ability  to  generate  NP pep- 
tide-specific CTL clones from C57BL/6 mice immunized 
with PR8 or HK viruses. Upon in vitro culture of splenic 
lymphocytes with PRS-NP or HK-NP peptides, the cells were 
cloned at 1-3 cells/well and expanded for several rounds. The 
data depicted in Fig. 2 show that PR8-NP-specific CTLs lysed 
EL-4 cells coated with PR8-NP but not with HK-NP pep- 
tide,  and that  HK-NP-specific CTLs lysed only EL-4 cells 
coated with HK-NP peptide, Whereas 0.01/~M of PR8-NP 
and HK-NP peptides was required  to sensitize EL-4 target 
cells for significant  lysis by CTL clones,  1 /~M of peptide 
was necessary to reach the plateau of sensitization (data not 
shown). Similar results were obtained with RMA and RMA-S 
cells  (data not  shown). 
Competition of Binding of PR8-NP and HK-NP Peptides to 
Surface D b Glycoprotein.  A potential drawback to the use of 
virus transfectants,  as vaccines expressing multiple peptides 
specific for the same allele,  is that intramolecular  competi- 
tion may occur with one peptide being preferentially presented 
over others. The PR8-NP and HK-NP peptides differ by only 
two amino  acid residues,  and since the anchoring  residues 
are identical, they may be considered to be analogues. Thus, 
if intramolecular  competition  occurs, it should be demon- 
strable using these peptides.  To confirm that  they had this 
capability, we studied the competition at the level of peptide 
presentation by simultaneously incubating constant amounts 
of PR8-NP peptide with variable amounts of HK-NP pep- 
tide and vice versa.  When we incubated EL-4 cells with 10 
/~M PR8-NP peptide and various amounts (10-100 #M) of 
HK-NP peptide, little inhibition of lysis of EL-4 cells by PR8- 
NP-specific CTL was observed. Only a weak inhibition was 
also observed when 10 #M HK-NP peptide was incubated 
with various amounts of PRS-NP peptide and HK-NP specific 
CTLs (data not shown). In contrast, a strong inhibition was 
observed when only 1 #M of PR8-NP peptide was simul- 
taneously incubated with the HK-NP peptide or with pep- 
tides  derived  from  SV40  virus  which  are  recognized  by 
CD8 + T  cells in association with the D b MHC class I gly- 
coprotein (see Fig. 3 A). This was also true when EL-4 cells 
were simultaneously incubated with 1 #M HK-NP peptide 
and various amounts of PRS-NP or the SV40 peptides (Fig. 
3 B). These results suggest that PRS-NP and HK-NP pep- 
tides display a similar a~nity for the D b class I MHC gly- 
coprotein and have the potential to compete with one an- 
other for occupancy in  the D b binding  site. 
We incubated the target cells for 30 min with PR8-NP 
or HK-NP peptides, and then washed and incubated them 
for 2 h with various amounts of analogues.  No inhibition 
of lysis of EL-4 cells by PR8-NP or HK-NP specific  CTL 
was observed (data not shown).  These results suggest that 
the two peptides have similar afhnities for the MHC molecules. 
Presentation of the PR 8-NP Peptide Expressed within the HA 
of Influenza Virus Transfectant RIO.  In preliminary  experi- 
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Figure 2.  Specific lysis of EL-4 
cells coated with PR8-NP or HK- 
NP peptides by PR8-NP or HK-NP 
peptide-specific  CTL clones.  (11) 
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Figure  3.  Inhibition of CTL activity by peptide analogs. (A) Specific  lysis by PR8-NP specific CTL clone of EL-4 cells simultaneously incubated 
with 1/~M PRS-NP peptide and varying amounts of HK-NP and SV40  peptides. (B) Specific  lysis  by HK-NP-specific  CTL clone of EL-4 cells simultane- 
ously incubated with 1/~M HK-NP peptide and varying amounts of PRS-NP and SV40 peptides. The experiments were carried out at a 40:1 E/T ratio. 
ments we investigated the presentation of the PR8-NP pep- 
tide expressed by the HA gene of the transfectant virus R10 
and that of PR8 virus which contains the peptide in the NP. 
C57BL/6 mice were immunized with PR8 virus and splenic 
lymphocytes were secondarily stimulated in vitro with SC 
coated with PRS-NP peptide. The CTL activity was deter- 
mined using PRS-NP peptide-sensitized E1r  target cells or 
cells infected with PR8 or R10 viruses. The data show that, 
as expected, cells from nonimmunized mice, whether or not 
secondarily stimulated with PRS-NP peptide-coated cells, 
did not lyse EL-4 cells (Fig. 4, A and B). Similarly, cells from 
PR8 virus-immunized mice which were not restimulated in 
vitro with PRS-NP peptide-coated cells did not lyse EL4 
cells (Fig. 4 C). In contrast, cells from PR8 virus-immunized 
mice after secondary in vitro stimulation with PRS-NP pep- 
tide-coated SC, lysed EL-4 target cells coated with homolo- 
gous peptide or infected with PR8 or R10 viruses (Fig.  4 
D). These results show that  the PRS-NP peptide is gener- 
ated from the PR8 virus NP as well as from the R10 virus 
HA and that it is efficiently presented to CTL. More impor- 
tantly, the NP peptide generated from the R10 HA was im- 
munogenic in vivo since upon in vitro incubation with PR8- 
NP peptide-coated SC, cells from mice immunized with R10 
virus were able to lyse EL-4 target  cells infected with R10 
or PR8 viruses or sensitized with PRS-NP peptide (Fig.  4 
F). These results demonstrate that the same core peptide ex- 
pressed in genes coding for different viral proteins can prime 
the peptide-specific CTL precursors  in vivo. 
The results were confirmed by experiments in which splenic 
lymphocytes from mice immunized with PRS, HK or R10 
viruses were secondarily stimulated in vitro with PR8-NP 
or HK-NP peptide coated SC, and then tested for CTL ac- 
tivity on PRS,  HK,  or R10 virus infected Eb4 cells.  The 
data depicted in Table  1 show that  as expected,  cells from 
nonimmunized  mice do not exhibit CTL activity upon in 
vitro stimulation  with PR8-NP or HK-NP peptide-coated 
SC. Cells from PR8 virus-immunized mice stimulated secon- 
darily in vitro with PR8-NP-coated SC do not exhibit cyto- 
toxic activity against HK virus-infected cells, however, they 
lyse target cells infected with PR8 or gl0 viruses. In con- 
trast, cells stimulated with HK-NP peptide-coated SC show 
a low but significant lytic capacity of EL-4 target cells in- 
fected with PR8 or R10 viruses. This activity can be attrib- 
uted to cross-reactive CTL (25) that were primed in vivo and 
that are not eliminated by a single cycle of in vitro stimula- 
tion with peptides, the method used to generate CTL clones. 
Cells from mice immunized with  HK virus show a signi- 
ficantly lower frequency of cross-reactive clones since upon 
in vitro stimulation with PRS-NP peptide-coated SC, low 
lytic activity is observed using target cells infected with PR8, 
HK, and R10 viruses. After in vitro stimulation  with HK- 
NP peptide-coated SC,  these cells  showed significant lysis 
of EL-4 target  cells  infected with  HK and R10 viruses. 
It  is  important  to  note  that  whereas  CTLs  from  PR.8 
virus-primed mice stimulated in vitro with HK-NP peptide 
were able to kill target cells infected with PR8 virus, those 
four animals primed with HK virus did not. Asymmetrical 
expansion of CTLs from PR.8 virus-primed animals by HK- 
NP peptide suggest that the PR8 virus priming stimulated 
cross-reactive CTL or a discrete subset of CTLs exhibiting 
a promiscuous recognition. This may reflect the fact that PR8 
virus replicates much more efficiently in mice than HK virus. 
Table 1 also demonstrates that cells from animals immunized 
with R.10 virus stimulated in vitro with PRS-NP or HK-NP 
peptide-coated SC display cytotoxic activity against PR.8, HK, 
and R.10 virus-infected EL-4 cells. Thus,  the R.10 virus can 
prime in vivo CTL for lysing target cells infected with both 
PR8 and HK virus. 
These results clearly demonstrate  that the R10 virus can 
efficiently prime both NP specific  and cross-reactive CTLs 
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In vitro expansion of PR8-NP peptide-specific CTL obtained from mice that were immunized with PR8 virus or transfectant virus RI0. 
207  Isobe et al. Table  1.  In  Vivo Priming  of CTL  by RIO Influenza  Virus  Transfectant 
In vitro 
Mice  Number  of  stimulation 
mmunized  mice  with  spleen cells 
with  started  coated with  PR8  virus 
EL-4  cells infected with 
HK virus  R.IO virus 
Saline  4 
PR8 
virus 
NK virus 
R10 virus 
nil 
PR8  NP 
HK NP 
nil 
1.2 
0.8 
0.8 
2.5 
6  PR8  NP  43.7 
HK NP  28.6 
nil  1.2 
6  PR8  NP  11.2 
HK NP  12.6 
nil  3.7 
6  PR8  NP  33.9 
HK NP  18.2 
-+  1.5" 
+_  1.2 
+-  1.0 
+  1.8 
+  21.5 
+_  12.2 
_+  1.0 
+  3.2 
+  4.6 
+  2.8 
+  16.8 
+  6.5 
1.3  _+  1.1 
0 
0 
0.3  _+  0.3 
2.2 
1.6 
1.0 
6.1 
37.7 
5.8 
43.5 
45.7 
0 
0 
0 
0 
_+  2.4  35.8  _+  10.9 
+_  2.7  37.4  +  6.2 
_+  1.9  0.1  +_  0.4 
+  7.3  14.1  _+  9.3 
_+  21.9  38.9  _+  8.0 
+_  5.2  0 
+  13.0  36.6  _+  16.0 
+_  24.0  37.2  +_  11.6 
All the experiments  were performed  at  a 30:1  E/T ratio. 
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Figure  5.  Comparison oflysis of 
EL-4, RMA, and RMA-S cells in- 
fected  with  PRS,  HK,  or  R10 
viruses by PRS-NP peptide-specific 
CTL. 
208  Two NP Peptides Expressed by a Single Virus Figure 6.  Expression  of HA on the surface  of RMA-S cell infected  with PR8 and R10 viruses. RAM-S cells were incubated  for 60 min with PR8 
or R10 seed virus, washed, and cultured overnight. 5  x  104 RMA-S-infected  cells were fixed for 5 min with 1% paraformaldehyde,  washed, and 
incubated for 60 min with mAb (10/~g/ml). After  washing, the cells were incubated  for 45 min with peroxidase-labeled  goat anti-mouse  lgG (1:500 
dilution), washed twice, and incubated  in AEC substrate medium according to the manufacturer's  instructions  (Dako, Copenhagen, Denmark). (a) 
Immunostaining: virtually  all cells infected  with PR8 virus are stained after incubation  with FY211 mAb-specifi~  for PK8 virus HA (H1). x200. 
(b) Immunostaining:  the majority  of cells infected  with R10 virus are stained after incubation  with 2G9 mAb specific  for WSN virus HA  x  200. 
(c) Immunostaining:  lack of staining of cells infected  with R10 virus after incubation  with PY206 mAb-specific for X31 virus HA (H3). x200. 
compared with PR8 or HK viruses.  It is also possible  that 
within APCs infected with R10 virus, both PR8 and HK- 
NP peptides are generated and therefore CTL precursors  ex- 
hibiting specificities for these peptides were expanded. These 
results, taken together, indicate that both peptides are gener- 
ated from R10-transfectant virus.  Whether residing in the 
chimeric HA or the native NP molecule, they are efficiently 
presented by D b MHC  and are  able to  expand precursor 
CTL in vivo and be recognized by CTL effectors in vitro. 
Presentation by RMA-S Cells of  NP Peptides  Expressed by the 
HA and the NP Transfectant Virus RIO.  It has been reported 
that peptides derived from a signal sequence  are processed 
by a transporter-independent  pathway (26, 27). Since the PR8- 
NP peptide is harbored in the HA and has a signal sequence, 
whereas the HK-NP peptide is carried by the NP protein which 
is devoid of a signal  sequence,  it seemed possible  that the 
HA peptide might be presented in the TAP-defective RMA-S 
cell line whereas the NP peptide would not. RMA-S cells 
have a defect in MHC class I assembly due to a defined muta- 
tion in the TAP-2 gene (21) that prevents expression of trans- 
porter molecules (28).  These transporters are believed to be 
involved in the translocation of peptides to the endoplasmic 
reticulum (ER) where they encounter MHC class I glyco- 
proteins (29,  30). 
The control experiments show that both EL-4 (Fig.  5 a) 
and RMA (Fig. 5 b) cells infected with PR8 or R10 viruses 
(and not those infected with HK virus), are lysed by PR8 
NP-specific CTL. The specific lysis of  PR8 virus-infected cells 
was somewhat higher than that of cells infected with R10 
virus. This difference reflects the reduced infectivity titer of the 
transfectant virus (10  s TCIDs0/ml) relative  to that of PR8 
virus (2.8  x  109 tissue culture infectious dose [TCID]s0/ml). 
Although RMA-S cells sensitized with PR8-NP or HK-NP 
peptides were efficiently lysed by PR8-NP or HK-NP specific 
CTL (data  not shown), lysis was not observed  in the case 
of RMA-S cells infected with PR8 or R10 viruses (Fig. 5c). 
Lack of lysis of RMA-S target cells infected with PR8 or 
R10 viruses was not related to a defective production of the 
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cells as demonstrated by immunostaining with mAbs specific 
for the HA of PR8 or WSN viruses, respectively. (Fig. 6). 
The presence of  HA of PK8 and WSN viruses on the surface 
of cells infected with  R10  viruses was  also visualized by 
hemadsorption (data not shown). Thus, the inability to lyse 
RMA-S-infected cells suggests that both peptides are processed 
by a transporter-dependent  pathway. 
Discussion 
Solution  at  2.4  A  resolution  of the  structure of the 
H-2D  b glycoprotein associated with the NP peptide (amino 
acids 366-374) of the PR8 virus has recently been reported 
(31). The structure reveals  a hydrophobic ridge in the antigen- 
binding deft of the glycoprotein, produced by the side chains 
of Trp73, Tyr156, and Trp147. This ridge was shown to be 
responsible for a bulge in the backbone of the bound peptide 
at P6,  P7,  and P8 that causes these peptide residues to be 
directed out of the cleft towards external solvent. Based on 
the high solvent-accessible surface areas of P6M,  P7E, and 
P8T, Young et al. (31) suggested that these residues are avail- 
able for contact by the TCR. 
Our experimental data are in agreement with this predic- 
tion since CTL specific for the PR8-NP peptide (P7E and 
P8T) cannot lyse target cells coated with the HK-NP pep- 
tide (P7D and P8A) and HK-NP-specific CTL clones cannot 
lyse EL-4 cells coated with the PR8-NP peptide. Hence, since 
the identity of the side chains of the peptide residues at P7 
and P8 are crucial to CTL recognition, these peptide residues 
must be involved in contact with the TCR.  Fig.  7 shows 
the conformation of the PR8-NP peptide from the 2.4 A 
resolution crystal structure. Superimposed on this are P7 and 
P8 from a model of  the HK-NP peptide, obtained by replacing 
Glu and Thr at P7 and P8 of the PR8-NP peptide with Asp 
and Ala, respectively,  and then performing 100 cycles  of  energy 
minimization using Insight (Biosym Technologies,  CA). From 
this model,  we predict  that the differing CTL response of 
the two peptides is due to the fact that the HK-NP peptide 
has a smaller surface area available to the TCK,  as a result 
of its having smaller side chains at P7 and P8 than the PR8- 
NP peptide. 
Figure 7.  The 2.4 ~,resolution structure of the PR-NP peptide (gray) 
and P7 and P8 of a model of the HK-NP peptide (black). Peptides  are viewed 
from the side, looking from the oe2 helix toward the c~1 helix of the H-2Db 
molecule. Figure produced using Molscript  (55). 
Our results suggest that the two NP-specific  peptides have 
similar affinity for the MHC molecule. When 1 #M PRS- 
NP  peptide  was  incubated  simultaneously  with  varying 
amounts of HK-NP or of two SV40 peptides, similar levels 
of  inhibition of  target cell lysis  by PR8 NP-specific  CTL were 
observed. Comparable results were obtained when the cells 
were incubated with HK-NP peptide and varying amounts 
of PRS-NP or SV40 peptides. The conclusion that PRS-NP 
and HK-NP peptides have similar affinities for the D b MHC 
glycoprotein was strengthened by experiments in which EL-4 
cells were first incubated with a peptide for 30 min, washed, 
and then incubated for 2 h with peptide analogues. In this 
case, lysis of EL-4 cells was not inhibited by the addition of 
peptide analogues. This result suggests that a peptide bound 
to surface class I molecules cannot be easily displaced by ana- 
logues. 
We sought to determine, based on these findings, whether 
there is competition between the PRS-NP and the HK-NP 
peptides when they are expressed by the HA and NP pro- 
teins of  the same virus. This is important if transfectant viruses 
such as R10 are to be used as vaccines, since peptides specific 
for a single allele may compete with one another for presen- 
tation. 
Our results strongly suggest that in cells infected with the 
transfectant virus R10 both peptides are presented efficiently. 
Indeed, EL-4  cells infected with R10 virus were lysed by both 
PR8-NP and HK-NP peptide-specific CTLs.  Furthermore, 
immunization of  mice with R10 virus primed the precursors 
of both PRS-NP and HK-NP peptide-specific CTLs. These 
results are of twofold importance. First, they show that the 
PRS-NP peptide expressed by the HA of R10 virus is pro- 
cessed like the HK-NP peptide carried by the NP protein 
and therefore that it appears that the location of the epitope 
has little influence on its presentation  in this  system. Our 
data strengthen previous observations that a peptide recog- 
nized by T  cells can be generated independent of flanking 
regions (23, 32, 33, 34). Actually, recent data showed that 
an influenza virus HA epitope recognized by CTL could be 
moved to a different site within the HA without precluding 
its generation from various locations and recognition by CTLs 
(35). Second, lack of competition between the peptides in 
our system suggests that live influenza viruses may be good 
vectors for presenting multiple CTL epitopes useful for the 
immunization of outbred species. 
Whereas the CTL clones generated from acutely infected 
mice with PR8 or HK viruses and repeatedly stimulated in 
vitro with NP peptide exhibited high specificity for PR8 or 
HK-NP peptides, the polyclonal CTL obtained from animals 
infected with PR8 or R10 viruses exhibited cross-reactivity. 
Thus, CTLs from animals primed with PR8 virus and secon- 
darily stimulated  with HK-NP peptide lysed PRS-infected 
cells or secondarily stimulated with PR8-NP peptide lysed 
HK-infected cells. 
There is little information on cross-reactivity in the rec- 
ognition of unrelated viral antigens. Cross-reactive recogni- 
tion was reported in the case of human CTL  specific for 
influenza matrix protein and VP4 peptide of  human rotavirus 
(36), as well as murine CTLs specific for influenza virus NP 
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choriomeningitis virus (LCM), Pichinde, and vaccinia viruses 
(39). Furthermore, cross-reactivity was also reported at a pro- 
tective level (i.e., heterosubtypic immunity) against X31 virus 
in tracheal and lung CD8 + T  cells of animals immunized 
with PR8  virus (40). 
Several hypotheses can be entertained to explain the pres- 
ence of cross-reactive CTLs in a fraction of polyclonal popu- 
lation obtained from mice infected with PR8 or R10 viruses. 
The possibility of the presence of leader sequence in the chi- 
meric HA molecule expressing PR8-NP epitope is in agree- 
ment with  the observation reported by Bacik  et  al.  (41) 
showing that leader sequence enhanced the degree of cross- 
recognition of vesicular stomatitis virus (VSV)  peptide by 
Sendai virus NP-specific CD8 + T cells. In addition, stimu- 
lation of memory cells that cross-react at a remote level with 
MHC-heterologous peptide complex may be due to enhanced 
expression of IL-2R or adhesion molecules that render the 
precursors more sensitive  to low affinity peptides. 
It is generally accepted that the peptides derived from pro- 
teins  synthesized within  the  cytoplasm  are  generated by 
proteasome-associated enzymes and that they are then trans- 
ported by TAP transporters to the ER where they bind to 
class I molecules (21, 42). The lack of competition is consis- 
tent with the observation that TAP contains a recognition 
peptide site with broad specifidty (43) and that anchor residues 
important for the binding to class I molecules are not impor- 
tant for TAP recognition and translocation (44). 
It has been shown that peptides derived from signal se- 
quences themselves are not TAP dependent, suggesting that 
they are produced in ER by the action of signal peptidases 
(26, 27).  However, the majority of peptides generated from 
endogenous proteins without (28,  29)  or with (45)  signal 
sequences are TAP dependent. Addition of leader sequences 
to NH2, but not COOH-termini of peptides which can be 
presented in a TAP-independent pathway, enhances the pre- 
sentation in a TAP-dependent manner (41, 46). However, there 
are data indicating that signal sequences can bypass the re- 
quirement of TAP. Thus, Hammond et al. (47) showed that 
HIV-1 env protein is processed in infected cells after its cotrans- 
lation  and  translocation  into  ER  via  a  TAP-independent 
pathway. Similarly, the addition of a signal sequence to an 
influenza virus matrix peptide can circumvent TAP deficiency 
in human mutant T2 cell lines. Mutant T2 cells expressing 
M57-68 peptide without signal sequence were not suscep- 
tible to lysis whereas those expressing the peptide with signal 
sequence were lysed by peptide-specific CTLs (48). 
Thus, it was interesting to determine whether NP pep- 
tides expressed by the HA or NP proteins may use different 
processing pathways leading to their presentation on the MHC 
class I molecules. To this end, we have studied the lysis of 
R10 virus-infected RMA-S cells by PR8-NP-specific CTLs. 
RMA-S mutant cells have a defect in the assembly of MHC 
molecules (28) due to a defined mutation (21) preventing the 
expression of the TAP-2 gene product, a transporter involved 
in antigen presentation. Spies et al. (29) and later Attaya et 
al. (49) have shown that CTL clones specific for the NP pep- 
tide were unable to kill influenza virus RMA-S-infected cells. 
In contrast, there are reports showing that RMA-S cells are 
leaky since they are able to present VSV, Sendai, and Rauscher 
virus-derived  peptides  (50-52).  Our  results  showed that 
whereas both EL-4 and RMA cells infected with PR8 or R10 
viruses are lysed by PR8-NP-specific CTLs, RMA-S cells in- 
fected with the same viruses are not. Our results are in agree- 
ment with the observation of Spies et al. (29) that RMA-S 
mutant cells do not present the peptides derived from the 
influenza virus NP. More importantly, we observed that RMA-S 
cells do not present the PR8-NP peptide expressed by the 
HA gene of the K10 virus. 
Failure of RMA-S cells to present the NP peptide expressed 
in the HA can be interpreted in two ways. First, the PRS- 
NP peptide is generated by the processing of the HA in the 
cytosolic compartment. A portion of native polypeptides with 
signal sequences are processed within the cytosol before trans- 
location to Elk allowing for a transporter-dependent antigen 
presentation. This finding is in conflict with data demon- 
strating that an influenza virus NP peptide located COOH- 
terminal to an ER insertion sequence was efficiently presented 
by TAP-deficient cells (48, 53).  A potential reason for this 
discrepancy is the location of the peptide versus  the leader 
sequence. Whether in the above mentioned experiment the 
peptide was located at COOH termini of the insertion se- 
quence, in R10 virus chimeric HA, the PR8-NP peptide was 
located in site E, distal to signal sequence. However, it is worth 
noting that it was found that signal peptides can function 
even when located far away from NH2 terminus of the pep- 
tide (54). Another possible explanation in the case ofpeptide 
minigene encoding signal  sequence is  that  the peptide is 
dumped in ER in a preprocessed form, whereas in the case 
of chimeric HA,  the molecule must be further processed. 
Alternatively, proteins with signal sequences are processed 
in the ER and transporter molecules are required within the 
Elk for the capturing of peptides by class I molecules. The 
latter hypothesis is supported by recent findings (44) that TAP 
molecules are complexed with newly assembled class I mole- 
cules.  The TAP disassociates  from this complex upon the 
binding of peptide to class I  (44). 
In summary, our study indicates that transfectant viruses 
expressing multiple immunogenic peptides presented by the 
same allelic MHC product can be used to expand precursor 
CTL in vivo and serve as targets for CTL lysis in vitro. Thus, 
such viruses can be used as vehicles  to introduce multiple 
immunogenic peptides into the endogenous processing path- 
way. It also suggests that the processing of proteins with sig- 
naling sequences occurs in the cytoplasm and that the influenza 
HA and NP viral proteins use the same transporter-dependent 
pathway for presentation to class I MHC antigens. Our results 
thus indicate the feasibility of genetically engineering recom- 
binant vaccines  that express  multiple epitopes to stimulate 
cellular immunity and that play an important role in the host 
defense against obligatory intraceUular parasites. 
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